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Introduction 
Aortofemoral graft infection is a rare but life-threat- 
ening complication ofabdominal aortic surgery which 
develops in about 0.7-2.8%. 14 Once occurred, the graft 
infection presents a very high mortality rate (14--55%), 1'3 
in particular in those cases who present secondary 
aortoenteric fistula. After removal of an infected aortic 
graft, distal revascularisation can be obtained with a 
new graft in an anatomic (in situ revascularisation) or 
extra-anatomic position. 7-9 Among the available grafts, 
biological prostheses seems to possess higher infection 
resistance.9 15 In 1987, Salles et al. 16 developed a new 
bovine pericardial conduit introducing the principle 
of crimping used for Dacron vascular prostheses. They 
used this conduit, after experimental studies, for re- 
placement of the thoracic and abdominal aorta as well 
as to correct different kinds of complex congenital 
cardiac lesions. The crimped bovine pericardium con- 
duit is obtained after a complex process. The resultant 
graft is a soft and flexible tube, fashioned in a straight 
or bifurcated esign, easy to handle and suture in 
aortic position. 
We started to use the bifurcated crimped bovine 
pericardium conduit in the revascularisation f isch- 
aemic areas after the removal of an infected aorto- 
femoral graft from 1993. The purpose of this paper is 
to assess whether there is a role for this biological 
compound in the management of graft infection. 
Materials and Methods 
From January 1991 to November 1995 we performed 
3542 arterial reconstructions with 639 grafts implanted 
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in aortic position, 566 (88.6%) for aortic aneurysm and 
73 (11.4%) for aortic occlusion. Twenty patients with 
aortofemoral graft infection (3.1% of the aortic surgery) 
underwent removal of the infected graft. There were 
19 men and one woman, with a mean age of 62 years 
(range 42-77). 
The clinical presentation of these 20 cases was an 
aortoenteric fistula in 12 cases (63%), seven (37%) 
melaena, six (31%) hypovolaemic shock, five (26%) an 
inguinal fistula, four (21%) inguinal abscess, three 
(16%) a retroperitoneal abscess, three (16%) a femoral 
pseudoaneurysm and two (10%) an aortic pseudo- 
aneurysm. In the inguinal area the isolated bacteria 
were Staphylococcus aureus in nine cases, Pseudomonas 
aeruginosa in one, while in the abdominal area were 
Gram-negative in the majority of the cases. All the 
removed grafts were Dacron. 
The previous vascular econstruction was an aorto- 
bifemoral graft in 12 cases (60%), a terminoterminal 
aortic replacement in three cases (15%), an aortobi- 
iliac replacement in two cases (10%), an aorto- 
monofemoral in one case (5%) and a femorofemoral 
crossover bypass in two cases (10%). The patients were 
divided into two groups: (1) group A--12 patients 
(60%) with aortoenteric fistula; (2) group B---eight 
patients (40%) without aortoenteric fistula. The sur- 
gical techniques adopted in the two groups of patients 
are shown in Tables 1 and 2. In group A patients the 
total removal of the infected graft was followed by 
extra-anatomical ( xillobifemoral) bypass in five cases, 
and by in situ revascularisation in four cases. In three 
patients this was the only surgical procedure. In group 
B patients this was performed in three cases, a partial 
removal of the graft followed by in situ reconstruction 
in two cases and by extra-anatomic (transobturatory) 
bypass; in five cases an aortobifemoral in situ re- 
construction followed the total removal. 
The in situ revascularisation was performed in nine 
cases. In five cases was adopted the crimped bovine 
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Table 1. Surgical treatment in group A patients (with aortoenteric 
fistula). 
No. Previous Mortality 
reconstruction 
Total removal 3 
Total removal ÷ EABP 5 
Total removal + alloplastic 1 
in situ 
Total removal + bovine 2 
pericardium insitu 
Total removal ÷ homograft 1 
in situ 
2 AOBF 2 
1 AOMF - -  
3 AOAO 2 
1 AOBI 1 
1 AOBF 
1 AOBF 
2 AOBF 1 
1 AOBF 
EABP=extranatomical bypass; AOBF=aortobifemoral bypass; 
AOAO = aortic replacement; AOBI = aortobi-iliac replacement. 
Table 2. Surgical treatment in group B patients (without aorto- 
enteric fistula). 
No. Previous Mortality 
reconstruction 
3 
2 1 AOBI 
1 AOBF 
1 1 AOBF 
3 1 AOBF 1 
2 FEFE 
2 2 AOBF --  
Partial removal + 
reconstruction: 
--In situ 
--Extra-anatomical 
Total removal + bovine 
pericardium insitu 
Total removal + homograft 
in situ 
AOBI = aortobi-iliac replacement; AOBF = aortobifemoral bypass; 
FEFE = femorofemoral bypass; Extra-anatomical = transobturatory 
bypass. 
per icardium conduit  was adopted (see patient list in 
Table 3) (two in group A and three in group B), in 
three cases an homologous  aorta f rom mult i -organ 
donor  (one in group A and two in group B), and in 
one case an alloplastic graft (in group A). 
Results 
The global mortal i ty of the series was 35% (seven 
patients) and the major leg amputat ion rate was of 
15% (three cases). In the two groups the results were 
different with a mortal i ty of 50% (six patients) in group 
A and of 12.5% (one patient) in group B. This second 
group, however,  included all the amputat ions (three 
patients: 37.5%). 
Compar ing  the mortal i ty with the surgical technique 
adopted it was evident that, in group A, the total 
Table 3. Crimped bovine pericardium conduits: clinical cases. 
Patient Sex Age Diagnosis Operation Outcome 
1 M 62 - INF.AOBF TOT.REM. + Good 
- ING.ABSC. in situ 
- AEF 
Bacteria: Staphylococcus, coagulase-negative 
2 F 68 - INF.AOBF TOT.REM. + Died 
- ING.ABSC in situ 
Bacteria: Salmonella rizonae 
3 M 58 - INF.FEFE TOT.REM. ÷ Good 
-ULC.INF.LEG in situ 
Bacteria: Staphylococcus haemolyticus 
4 M 59 - INF.AOBF TOT.REM. + Died 
-AEF in situ 
Bacteria: Escherichia coli + Staphylococcus, 
coagulase-negative 
5 M 76 - INF.FEPOP. TOT.REM. + Good 
- Septicaemia in situ 
Bacteria: Pseudomonas 
INF.=infected; AOBF=aortobifemoral bypass; FEFE=femoro- 
femoral bypass; ING.ABSC. =inguinal abscess; ULC.INELEG=ul- 
ceration inferior leg; AEF=aortoenteric f stula; TOT.REM. + in 
situ =total removal of the graft and in situ revascularisation with 
crimped bovine pericardium conduit; FEPOP-femoro-popliteal by- 
pass. 
removal  of the infected graft associated or not with 
an extra-anatomic bypass was affected with a h igh 
mortal i ty (five patients: 62.5%), while the in situ re- 
vascularisation presents a lower mortal i ty (one patient: 
25%). 
The in situ cr imped bovine per icardium group was 
affected by a mortal i ty of 40% (two patients: one in 
group A and one in group B). The cause of death was 
the recurrence of infection (group B patient) and a late 
failure of the duodenal  suture (group A patient). 
The 13 survivors were fol lowed up for a mean 
per iod of 18 months  (range 1-36). Dur ing this period 
one group A patient died from a myocardia l  infarction 
and three group B patients were readmitted for re- 
current infection. 
Discussion 
The treatment of choice in aortofemoral  graft infection 
is controversial. 4'5'7'9-13 None of the proposed techniques 
is universal ly accepted, with results vary ing greatly 
among different surgeons. In the last decade, various 
authors 9-13'15 have util ised biological prostheses in the 
management  of graft infection. Reports suggest that 
biological grafts seem to have higher infection re- 
sistance compared with prosthetic material. 14'~5 Among 
these authors, Kieffer 9'~5 has had good results with the 
use of fresh human homograf t  harvested from multi- 
organ donors and implanted in the infected fields. 
Together with other surgical departments,  we started 
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a program for the use of human arterial homograft 
but due to logistic and bureaucratic problems it is 
not always possible to have an arterial homograft 
available, especially in emergency situations. In these 
conditions the crimped bovine pericardium conduit 
represents an alternative substitute biological graft 
material. 
The number of grafts implanted and of patients in 
this group is too small to be statistically significant. 
In particular the follow-up period is too short to 
consider the real risk of infection recurrence and the 
biological resistance to the infection. However, the 
results of the series seem to suggest a possible role for 
this graft, as a bridge solution to the replacement of 
an alloplastic graft but also as a definitive solution. 
Further investigations will clarify those aspects. 
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